Patricia Van Arnum

See Patricia Van Arnum's bio page.

Following its $68-billion acquisition of Wyeth, Pfizer has unveiled detailed plans for its global R&D network, which includes consolidation of its R&D facilities.

Following the its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) Pfizer detailed plans for its global research and development (R&D) network, which includes consolidation of its R&D facilities.

Novartis reported that German regulatory authorities approved its adjuvanted cell culture-based Influenza A (H1N1) 2009 monovalent vaccine, Celtura. The company also said it will acquire a stake in Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical.

The European Medicines Agency, the European Center for Disease Prevention and Control, and the Heads of Medicines Agencies issued a European strategy for H1N1 vaccine benefit–risk monitoring.

Exhibitors announce capacity expansions, service enhancements, and new products at CPhI Worldwide in Madrid.

Vetter moves ahead with a new development facility in the US and expanded capabilities in Germany.

Leading experts from an upcoming conference on biosimilars by the Drug, Chemical, and Associated Technologies Association share their insights on the manufacturing and regulatory considerations for biosimilars.

The FDA has responded to a citizen petition from the Society of Chemical Manufacturers and Affiliates (SOCMA) that highlighted the disparity in inspections of domestic and foreign drug-manufacturing facilities.

Lonza (Switzerland) has announced a series of cost-cutting measures for the next 12¬–18 months.